Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04707391 · ClinicalTrials.gov registry record · Phase 3
Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,250
- Enrollment target
NCT04707391 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,250 participants.
The verdict
NCT04707391, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,250 participants
- Enrollment target
Study Summary
The purpose of this study was to assess immunogenicity and safety of MenABCWY vaccine in healthy adolescents and adults aged 15 to 25 years previously vaccinated with MenACWY vaccine.
Interventions
- COMBINATION_PRODUCT Placebo
- COMBINATION_PRODUCT MenABCWY vaccine
- BIOLOGICAL MenACWY vaccine
- COMBINATION_PRODUCT MenB vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,250 participants |
| Start Date | 2021-01-25 |
| Est. Completion | 2023-09-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04707391
The ClinicalTrials.gov registry entry for NCT04707391 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT04707391 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04707391 about?
NCT04707391 is a clinical study titled "Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine". The purpose of this study was to assess immunogenicity and safety of MenABCWY vaccine in healthy adolescents and adults aged 15 to 25 years previously vaccinated with MenACWY vaccine.
What is the current status of trial NCT04707391?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,250 participants. The study started on 2021-01-25. Estimated completion is 2023-09-29.
What interventions are being tested in trial NCT04707391?
The interventions under investigation include: Placebo (COMBINATION_PRODUCT), MenABCWY vaccine (COMBINATION_PRODUCT), MenACWY vaccine (BIOLOGICAL), MenB vaccine (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04707391?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.